245 related articles for article (PubMed ID: 33534893)
1. BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation.
Jia W; Poe JC; Su H; Anand S; Matsushima GK; Rathmell JC; Maillard I; Radojcic V; Imai K; Reyes NJ; Cardona DM; Li Z; Suthers AN; Curry-Chisolm IM; DiCioccio RA; Saban DR; Chen BJ; Chao NJ; Sarantopoulos S
Blood; 2021 May; 137(18):2544-2557. PubMed ID: 33534893
[TBL] [Abstract][Full Text] [Related]
2. B cells in chronic graft-versus-host disease.
McManigle W; Youssef A; Sarantopoulos S
Hum Immunol; 2019 Jun; 80(6):393-399. PubMed ID: 30849450
[TBL] [Abstract][Full Text] [Related]
3. An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.
Poe JC; Jia W; Su H; Anand S; Rose JJ; Tata PV; Suthers AN; Jones CD; Kuan PF; Vincent BG; Serody JS; Horwitz ME; Ho VT; Pavletic SZ; Hakim FT; Owzar K; Zhang D; Blazar BR; Siebel CW; Chao NJ; Maillard I; Sarantopoulos S
Blood; 2017 Nov; 130(19):2131-2145. PubMed ID: 28851699
[TBL] [Abstract][Full Text] [Related]
4. Increased BCR responsiveness in B cells from patients with chronic GVHD.
Allen JL; Tata PV; Fore MS; Wooten J; Rudra S; Deal AM; Sharf A; Hoffert T; Roehrs PA; Shea TC; Serody JS; Richards KL; Jagasia M; Lee SJ; Rizzieri D; Horwitz ME; Chao NJ; Sarantopoulos S
Blood; 2014 Mar; 123(13):2108-15. PubMed ID: 24532806
[TBL] [Abstract][Full Text] [Related]
5. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.
Jacobson CA; Sun L; Kim HT; McDonough SM; Reynolds CG; Schowalter M; Koreth J; Cutler CS; Ho VT; Alyea EP; Armand P; Blazar BR; Soiffer RJ; Antin JH; Ritz J; Sarantopoulos S
Biol Blood Marrow Transplant; 2014 May; 20(5):668-75. PubMed ID: 24462743
[TBL] [Abstract][Full Text] [Related]
6. Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice.
Radojcic V; Paz K; Chung J; Du J; Perkey ET; Flynn R; Ivcevic S; Zaiken M; Friedman A; Yan M; Pletneva MA; Sarantopoulos S; Siebel CW; Blazar BR; Maillard I
Blood; 2018 Nov; 132(20):2188-2200. PubMed ID: 30181175
[TBL] [Abstract][Full Text] [Related]
7. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
Sarantopoulos S; Stevenson KE; Kim HT; Cutler CS; Bhuiya NS; Schowalter M; Ho VT; Alyea EP; Koreth J; Blazar BR; Soiffer RJ; Antin JH; Ritz J
Blood; 2009 Apr; 113(16):3865-74. PubMed ID: 19168788
[TBL] [Abstract][Full Text] [Related]
8. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.
Allen JL; Fore MS; Wooten J; Roehrs PA; Bhuiya NS; Hoffert T; Sharf A; Deal AM; Armistead P; Coghill J; Gabriel DA; Irons R; Essenmacher A; Shea TC; Richards K; Cutler C; Ritz J; Serody J; Baldwin AS; Sarantopoulos S
Blood; 2012 Sep; 120(12):2529-36. PubMed ID: 22896003
[TBL] [Abstract][Full Text] [Related]
9. Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.
Daenthanasanmak A; Iamsawat S; Chakraborty P; Nguyen HD; Bastian D; Liu C; Mehrotra S; Yu XZ
Blood; 2019 Jan; 133(3):266-279. PubMed ID: 30514750
[TBL] [Abstract][Full Text] [Related]
10. Chronic GvHD decreases antiviral immune responses in allogeneic BMT.
Hossain MS; Roback JD; Pollack BP; Jaye DL; Langston A; Waller EK
Blood; 2007 May; 109(10):4548-56. PubMed ID: 17289817
[TBL] [Abstract][Full Text] [Related]
11. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
12. Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
Yang K; Chen Y; Qi H; Ye Y; Fan Z; Huang F; Zhang H; Suo Y; Liu Q; Jin H
Front Immunol; 2020; 11():1505. PubMed ID: 32849514
[TBL] [Abstract][Full Text] [Related]
13. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
14. Modeling Chronic Graft Versus Host Disease in Mice Using Allogeneic Bone Marrow and Splenocyte Transfer.
Schroeder MA; Ashami K; Staser K
Curr Protoc Pharmacol; 2018 Dec; 83(1):e47. PubMed ID: 30204297
[TBL] [Abstract][Full Text] [Related]
15. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.
Srinivasan M; Flynn R; Price A; Ranger A; Browning JL; Taylor PA; Ritz J; Antin JH; Murphy WJ; Luznik L; Shlomchik MJ; Panoskaltsis-Mortari A; Blazar BR
Blood; 2012 Feb; 119(6):1570-80. PubMed ID: 22072556
[TBL] [Abstract][Full Text] [Related]
16. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.
Sarantopoulos S; Stevenson KE; Kim HT; Bhuiya NS; Cutler CS; Soiffer RJ; Antin JH; Ritz J
Clin Cancer Res; 2007 Oct; 13(20):6107-14. PubMed ID: 17947475
[TBL] [Abstract][Full Text] [Related]
17. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
[TBL] [Abstract][Full Text] [Related]
18. Thioredoxin-1 confines T cell alloresponse and pathogenicity in graft-versus-host disease.
Sofi MH; Wu Y; Schutt SD; Dai M; Daenthanasanmak A; Heinrichs Voss J; Nguyen H; Bastian D; Iamsawat S; Selvam SP; Liu C; Maulik N; Ogretmen B; Jin J; Mehrotra S; Yu XZ
J Clin Invest; 2019 May; 129(7):2760-2774. PubMed ID: 31045571
[TBL] [Abstract][Full Text] [Related]
19. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT.
Solano C; Martinez C; Brunet S; Tomás JF; Urbano-Ispizua A; Zuazu J; Ojeda E; Bargay J; Moraleda JM; Bailen A; Sierra J; García-Conde J; Rozman C
Bone Marrow Transplant; 1998 Dec; 22(12):1129-35. PubMed ID: 9894714
[TBL] [Abstract][Full Text] [Related]
20. Early Notch Signals Induce a Pathogenic Molecular Signature during Priming of Alloantigen-Specific Conventional CD4
Chung J; Radojcic V; Perkey E; Parnell TJ; Niknafs Y; Jin X; Friedman A; Labrecque N; Blazar BR; Brennan TV; Siebel CW; Maillard I
J Immunol; 2019 Jul; 203(2):557-568. PubMed ID: 31182480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
